Our innovative platform aids in the rapid and systematic development of optimized bioprocesses, and specifically helps to standardize and streamline cell line development.
Lille, France (PRWEB) June 24, 2013
Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced that it is extending its enterprise biologics R&D solution to support bioprocess development workflows. A first-in-class software solution for integrated biopharma data management, Genedata Biologics enables biologics companies to more efficiently discover, develop, and manufacture novel, as well as generic, biotherapeutics. Genedata Biologics provides tailored functionalities to enhance process efficiency, which complement established antibody discovery and protein engineering functionalities. Genedata Biologics will present its latest platform developments that support cell line and process development during the 23rd European Society for Animal Cell Technology (ESACT) Meeting (Lille Grand Palais; June 23 – 26).
Towards an Integrated Platform for Cell and Process Development: Significant Efficiency and Quality Gains
Genedata Biologics, an enterprise workflow system, now also supports process and cell line development units. The platform provides tools for the optimization of protein expression, purification, and analytics processes. These tools are essential for efficient and successful production of high-quality biologics for R&D and large-scale product manufacturing. Optimizing expression and purification processes requires various groups to work in a division-of-labor environment (e.g. molecular biology, cell line engineering, assays and analytics, and bioprocess development groups). Genedata Biologics captures all relevant data, from the definition of the desired biomolecule’s blueprint to the final product, including all production process-relevant parameters (e.g. transfection protocols, cell culture and fermentation conditions, media, purification methods, and product titers and quality parameters). All data are traced back to the plasmids and cell lines and can be analyzed together. The system also integrates with upstream and downstream processes, and now comes with sample and inventory management that streamlines tracking of samples and aliquots.
The system provides easy-to-use, comprehensive, and automated data capture, processing and reporting capabilities. It minimizes duplication of work, eliminates error-prone manual activities, and provides extremely valuable transparency for efficient decision making, so that high-quality proteins can be delivered faster.
“Having successfully supported important workflows in biopharma discovery, we now set our sights on extending Genedata Biologics to biopharma development with an initial focus on cell line and bioprocess development,” said Dr. Othmar Pfannes, CEO of Genedata. “Our innovative platform aids in the rapid and systematic development of optimized bioprocesses, and specifically helps to standardize and streamline cell line development. This brings us another step closer in providing our customers with a fully integrated platform that supports the complete biopharmaceutical R&D process.”
ESACT Editorial Note: June 24 and 25 from 12:30 – 14:30 CEST, Genedata Biologics will present the following posters: “Genedata Biologics - An Integrated Data Management Platform for Biopharmaceutical R&D” and “Biologics Expression System Optimization and Bioprocess Development.” To schedule a briefing contact jackie.thrasivoulos(at)genedata(dot)com.
Genedata transforms data into intelligence with a portfolio of advanced software solutions, which make research data accessible and understandable and research processes more efficient. These solutions are used worldwide by leading pharmaceutical, industrial, and agricultural biotechnology companies as well as academic research organizations. Genedata innovations enable scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Germany, Japan, and the US.
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.